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Abstract. Experts have called attention to the possible negative impact of the coronavirus disease 2019 (COVID-
19)–related cytokine storm syndrome on the progression of leprosy-related disabilities. We assessed the frequency of
reactional states in patients co-infected with Mycobacterium leprae and severe acute respiratory syndrome (SARS)
coronavirus (CoV) 2 (SARS-CoV-2).We consecutively included patients during the first peak of theCOVID-19 epidemic in
Brazil and analyzed the expressions of genes encoding interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12A, IL-12B, and tumor
necrosis factor-α in peripheral blood mononuclear cells. We included 64 leprosy patients and 50 controls. Twelve of the
leprosy patients and 14 of the controls had been diagnosed with COVID-19. Co-infection was associated with increased
IL-6 (P = 0.043) and IL-12B (P = 0.017) expression. The median disability grades were higher for leprosy/COVID-19
patients; however, the difference was not significant (P = 0.194). Patients co-infected with M. leprae and SARS-CoV-2
may experience a higher-grade proinflammatory state.
The outbreak of the new coronavirus disease 2019 (COVID-
19) has alarmed healthcare professionals. The increased
mortality rates associated with COVID-19 are a result of
hypercytokinemia, which is also referred to as cytokine storm
syndrome.1,2 Despite global efforts to contain the spread of
COVID-19, it has reached all continents.1 Leprosy is a chronic
infectiousdiseasecausedbyMycobacterium leprae that is still
endemic in highly populated countries suchasBrazil.3 Despite
its infectious nature, the disease has an important autoim-
mune background. Soluble factors derived from the bacillus
can stimulate immune reactions, ultimately resulting in acute
clinical pictures called leprosy reactional states.4,5
The onset of the COVID-19 pandemic has hindered the
proper management of leprosy patients because the social
distancing strategies may act as an important barrier to
accessing polychemotherapy. Recently, experts in the field
called attention to the possible negative impacts of cytokine
stormsyndromeon the progressionof leprosy.6,7 As seenwith
other infections, severe acute respiratory syndrome (SARS)
coronavirus (CoV) 2 (SARS-CoV-2) infection in patients with
leprosy may stimulate refractory reactional states.
We aimed to assess the frequency of reactional states in
leprosy patients after recovery from COVID-19 and to mea-
sure the impact ofM. leprae and SARS-CoV-2 co-infection on
the immunological response by measuring gene expressions
in a controlled clinical model.
We performed a cross-sectional study and consecutively
included patients attending the Leprosy Ambulatory Clinic of
the University Hospital of Brası́lia, Brazil, fromApril to October
2020, during the first peak of the COVID-19 outbreak in mid-
western Brazil. The professionals at this ambulatory clinic are
responsible for diagnosing cases of leprosy and performing
differential diagnoses. We excluded any immunosuppressed
patients other than thoseusingprednisone for the treatment of
leprosy reactions. The effects of the duration of the first
symptoms of COVID-19 and other relevant variables were
measured, including the occurrence of leprosy reactional
states after COVID-19.
To assess the association of gene expression with cytokine
levels, blood was obtained from each patient and tumor ne-
crosis factor (TNF)-α, interleukin (IL)-10, IL-1β, IL-8, IL-6 and
IL-12p70 were measured in the plasma using the Human In-
flammatory Cytokine Cytometric Bead Array - I Kit (RUO)
(Becton Dickinson, Franklin Lakes, NJ) in a FACSVerse flow
cytometer (Becton Dickinson). Peripheral blood mononuclear
cells (PBMCs) were isolated using Ficoll® Paque Plus (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden) gradient
centrifugation. High-molecular-weight RNA was purified us-
ing the mirVANA Paris Kit (Thermo Fisher Scientific, Waltham,
MA) with 700 μL of PBMCs. RNA was quantified spectro-
photometrically (NanoDrop 2000/2000c; Thermo Fisher
Scientific). Then, 100 ng of cDNA was prepared using the
High-Capacity RNA Reverse Transcription kit (Thermo Fisher
Scientific). Gene expression assays were performed for the
immunemediators TNF-α, IL-10, IL-1β, IL-8, IL-6, IL-12A, and
IL-12B using quantitative polymerase chain reaction (PCR)
with TaqMan-specific reagents (Thermo Fisher Scientific) on
QuantStudio 1 (Thermo Fisher Scientific) and standard set-
tings. Relative quantification was based on a β-globulin target
using the 2−ΔΔCq method.8
Data analysis was performed with statistical software R
version 4.0.3 (R Foundation for Statistical Computing, Vienna,
Austria). The final model consisted of a multivariable linear
regression in which cytokine gene expression values were
considered the dependent variables and clinically relevant
variables that could influence gene expression levels (COVID-
19 diagnosis, leprosy diagnosis, and the use of prednisone or
an equivalent at a daily dosage of 1 mg/kg/day after COVID-
19) were considered the independent variables. P < 0.05
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indicated that the independent variable significantly influ-
enced cytokine expression. All patients were included
after signing an informed consent form. This study was
approved by Brazil’s National Committee of Ethics (CAAE
34164820.6.0000.0030).
We included 114 consecutive patients; 64 were leprosy
patients (before, during, and up to 3 years after the end of
polychemotherapy for leprosy) and 50 were controls (who
attended the leprosy ambulatory clinic and were not di-
agnosed with leprosy). Twelve leprosy patients (mean time
since the onset of COVID-19, 43.54 days; range, 6-75 days)
and 14 nonleprosy patients (mean time since the onset of
COVID-19, 41.84 days; range, 6-90 days) reported having
been diagnosed with COVID-19 based on reverse-
transcriptase PCR amplification of SARS-CoV-2 RNA from
upper airway samples. The demographic characteristics of
each group are shown in Table 1. No patient needed intensive
care support; therefore, it was not possible to compare pa-
tientswith severe casesofCOVID-19 to thosewithmild cases.
The time from the onset of COVID-19 until inclusion was not
different between the two groups (P = 0.899). The levels of the
tested cytokines were not related to the time from the onset of
COVID-19 to inclusion. The number of previous bacille
Calmette-Guerin (BCG) vaccine doses was not related to the
gene expression profiles. No patients reported having used
medications intended to have a suppressive effect on SARS-
CoV-2. According to the institutional protocol, when leprosy
patients using high doses of corticosteroids were diagnosed
withCOVID-19, thedaily doseswere reduced to 20 to 40mgof
prednisone for 15 days.
We classified patients with paucibacillary andmultibacillary
leprosy based on the Ridley and Joplin criteria, but the leprosy
classification was not related to gene expression. The fre-
quencies of leprosy type I and type II reactions were similar
between patients with (33.3%) and without (42.30%) SARS-
CoV co-infection (P = 0.896). Absolute gene expression levels
of almost all tested cytokines were higher inM. leprae/SARS-
CoV-2 co-infected patients (Figures 1 and 2, Table 1). The
median disability gradewas higher forM. leprae/SARS-CoV-2
co-infected patients (median, 2; interquartile range [IQR], 1)
than for leprosy patients (median, 1; IQR, 1), but the difference
was not significant (P=0.194). Ourmultivariatemodel showed
that COVID-19 was related to increased expression levels of
TNF-α, IL-1β, IL-6, IL-8, IL-12B, and IL-10 (P < 0.05) (Table 1),
and that leprosy simultaneously enhanced the levels of IL-6
(P = 0.046) and IL-12B (P = 0.020) (Figure 1). The use of
prednisone reduced the level of IL-12B (P = 0.038). Gene ex-
pression analyses and flow cytometry yielded consistent
results.
As expected, our study showed that most of the cytokine
levels measured were higher in patients who had contracted
COVID-19 than in leprosy patients and controls, even at more
than 30 days after the onset of COVID-19. The proin-
flammatory cytokines TNF-α, IL-1β, IL-8, IL-6, and IL12-B
(P < 0.05) were increased in patients who had contracted
COVID-19. This result indicates a possible role of COVID-19 in
inflammation that could stimulate leprosy reactional states.2,6
The frequency of reactional states in patients co-infected
with M. leprae and SARS-CoV-2 was not greater than that in
patients with leprosy alone. However, clinicians must be
aware that most parameters for the detection of leprosy re-
actions rely on acute clinical signs of neurological pain, and
that silent neuropathy in leprosy is difficult to diagnose. This
may explain why the median disability grade was higher for
leprosy patients who contracted COVID-19. As an important
example, TNF-α expression is related to intense phagocytic
activity, which is also observed in type I leprosy reactions. IL-8
and IL-1β are related to neutrophil recruitment and are fre-
quently detected in the skin of leprosy patients experiencing
type I reactions.9
The expression of IL-6 was significantly increased in
leprosy/COVID-19 during our multivariate analysis. A recent
systematic review of the literature found increased levels of
IL-6 in patients with COVID-19.10 Clinical studies have shown
that single nucleotide polymorphisms in IL-6 genes are as-
sociated with leprosy reactions.11 In addition, IL-6 is a marker
TABLE 1
Fold-changes in the gene expression of TNF-α, IL-10, IL-1β, IL-8, IL-6, IL-12, and IL-12B and the adjusted effects of COVID-19, leprosy, and
reactional states according to the multivariate linear regression model
Demographic characteristics Leprosy/COVID-19 COVID-19 Leprosy Controls P value
Sex 0.482
Male, n (%) 7 (58.3%) 4 (28.6%) 24 (46.2%) 17 (47.2%)
Female, n (%) 5 (41.7%) 10 (71.4%) 28 (53.8%) 19 (52.8)
Age, years, mean (SD) 52.6 (11.2) 37.6 (16.3) 42.2 (13.9) 42.94 (15.63) 0.033
Type I reaction, n (%) 3 (25.0%) – 20 (38.5%) – 0.411
Type II reaction, n (%) 1 (8.3%) – 9 (17.3%) – 0.500
Disability grade, median (IQR) 2 (1) – 1 (1) – 0.194
Time since the onset of
COVID-19, days, mean (SD)
43.5 (19.9) 41.8 (26.8) – – 0.899
Multibacillary leprosy 10 (83.3%) 42 (80.8%) 0.885
Gene expression 2ΔΔCq (SD) P value*
TNF-α 11.1 × 105 (38.4 × 105) 15.8 × 102 (51.4 × 102) 10.5 × 103 (38.1 × 103) 598.46 (23.1 × 102) 0.061
IL-10 13.9 × 104 (48.1 × 104) 28.2 × 102 (64.6 × 102) 14.4 × 102 (36.5 × 102) 45.9 × 101 (17.5 × 102) 0.066
IL-1β 43.1 × 105 (49.4 × 105) 79.6 × 101 (14.7 × 102) 95.2 × 102 (37.7 × 103) 46.2 × 101 (17.8 × 102) 0.066
IL-8 36.1 × 105 (12.5 × 106) 13.9 × 102 (36.4 × 102) 20.5 × 103 (10.5 × 104) 45.1 × 101 (14.8 × 102) 0.066
IL-6 11.8 × 1010 (4.1 × 1010) 49.4 × 101 (1.3 × 103) 60.8 × 102 (2.0 × 104) 19.3 × 101 (6.7 × 102) 0.046
IL-12A 19.2 × 105 (66.5 × 105) 82.7 × 106 (30.9 × 107) 84.5 × 102 (48.9 × 103) 12.7 × 102 (64.2 × 102) 0.512
IL-12B 17.0 × 104 (48.4 × 104) 31.5 × 102 (63.3 × 102) 37.3 × 102 (25,342.95) 97.1 × 101 (3,886.18) 0.020
TNF = tumor necrosis factor; IL = interleukin; COVID-19 = coronavirus disease 2019; SD = standard deviation; IQR = interquartile range.
*P values were adjusted with a multivariate linear regression model and represent the influence of COVID-19 on the gene expression levels. P < 0.05 indicates that COVID-19 significantly
influenced the levels of cytokine expression.
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of neuropathic pain in leprosy, and patients with M. leprae/
SARS-CoV-2 co-infections may be at a greater risk for silent
neuropathy.12 This interesting result suggests the need for
investigations of the use of IL-6 inhibitors, such as tocilizu-
mab, to prevent neural damage.
Interestingly, our multivariate model also showed that IL-
12Bgene expressionwas increased in patientswithM. leprae/
SARS-CoV-2 co-infections. This cytokine is related to a cas-
cade of Th1 cellular responses13 also found in leprosy type I
reactions; however, its role in thepathogenesis ofCOVID-19 is
uncertain. IL-12B is closely related to the cellular response to
mycobacterial infections,14 and its elevation as a result of
M. leprae/SARS-CoV-2 co-infection introduces important
questions. Some experts in the field of infectious diseases
have hypothesized that patients living in countries with uni-
versal BCG vaccination could have a reduced likelihood of
contracting COVID-19.15 Could a constantly stimulated Th1
profile in patients with leprosy and their close contacts who
have undergone BCG vaccination reinforce this hypothesis?
One limitation of this study was that we were unable to test
other cytokines that are important in the pathogenesis of
leprosy reactions, including interferon-γ. Wewere also unable
to evaluate longitudinal changes throughout the course of
COVID-19. Cross-sectional methodology is useful for raising
questions; however, further longitudinal studies are needed to
test the real effects of this co-infection on the generation of
neuropathy.
We can conclude that M. leprae/SARS-CoV-2 co-infected
patients experience a prolonged inflammatory state after viral
infection. We were also able to observe that IL-6 and IL-12B
levels were increased in M. leprae/SARS-CoV-2 co-infected
patients, but clinically evident neuritis was not more common
in those patients. Therefore, clinicians must be vigilant for the
possibility of silent neuropathy in patients co-infected with
M. leprae and SARS-CoV-2, especially those with critical
cases of COVID-19.
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FIGURE 1. A dot plot of the four main groups included in the study. Group 1 includes patients co-infectedwithMycobacterium leprae and SARS-
CoV-2.Group2 includespatients infectedwithSARS-CoV-2but notM. leprae. Group3 includespatients infectedwithM. lepraebutnotSARS-CoV-
2. Group 4 includes control patients who were not infected with eitherM. leprae or SARS-CoV-2. P values were adjusted with a multivariate linear
regression model and represent the influence of leprosy on the gene expression levels. P < 0.05 indicates that leprosy significantly influenced the
levels of cytokine expression. This figure appears at www.ajtmh.org.
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Medicina Tropical, FaculdadeMedicina, Universidade de Brası́lia (UnB)
Brası́lia, Brazil, E-mail: cirogomes@unb.br.
This is an open-access article distributed under the terms of the
Creative Commons Attribution (CC-BY) License, which permits un-
restricted use, distribution, and reproduction in anymedium, provided
the original author and source are credited.
REFERENCES
1. de SouzaWMet al., 2020. Epidemiological and clinical characteristics
of the COVID-19 epidemic in Brazil.Nat Hum Behav 4: 856–865.
2. CoperchiniF,ChiovatoL,CroceL,MagriF,RotondiM,2020.Thecytokine
storm inCOVID-19: an overviewof the involvement of the chemokine/
chemokine-receptor system.Cytokine Growth Factor Rev 53: 25–32.
3. GurungP, GomesCM, Vernal S, LeeflangMMG, 2019. Diagnostic
accuracy of tests for leprosy: a systematic review and meta-
analysis. Clin Microbiol Infect 25: 1315–1327.
4. ShuKurizky P, dos SantosNeto LL, Barbosa Aires R, Henrique da
Mota LM, Martins Gomes C, 2020. Opportunistic tropical in-
fections in immunosuppressed patients. Best Pract Res Clin
Rheumatol 34: 101509.
5. World Health Organization, 2018. Guidelines for the diagnosis,
treatment and prevention of leprosy.WorldHealthOrganization
Guidelines 1: 1–87.
FIGURE 2. A heatmap showing increased levels of most measured cytokines in patients who had contracted coronavirus disease 2019 (COVID-
19). The plot was generated using the Thermo Fisher Scientific Cloud Environment (Thermo Fisher Scientific, Waltham, MA). This figure appears at
www.ajtmh.org.
4 SANTOS MORAIS AND OTHERS
6. Antunes DE, Goulart IMB, Goulart LR, 2020. Will cases of leprosy
reaction increasewithCOVID-19 infection?PLoSNegl TropDis
14: 1–4.
7. Santos VS, Quintans-Júnior LJ, de SouzaBarbozaW, Antunes de
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